• Anacor Pharmaceuticals Inc., of Palo Alto, Calif., reported results from its maximal use systemic exposure (MUSE) study of boron-based phosphodiesterase-4 inhibitor AN2728 in pediatric and adolescent patients, ages 2 to 18, with atopic dermatitis, with data showing that AN2728 ointment, 2 percent, appears to be safe, well tolerated and efficacious when applied twice daily.